Trials / Completed
CompletedNCT00693316
Safety and Tolerability Study With Single Ascending Doses of ORM-12741
Phase I Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study With Single Ascending Doses of ORM-12741
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 120 (actual)
- Sponsor
- Orion Corporation, Orion Pharma · Industry
- Sex
- Male
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to evaluate the safety and tolerability of escalating doses of ORM-12741 in healthy volunteers.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ORM-12741 | Alternating panel single dose escalation. |
Timeline
- Start date
- 2008-07-01
- Primary completion
- 2009-10-01
- Completion
- 2009-10-01
- First posted
- 2008-06-09
- Last updated
- 2010-02-11
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT00693316. Inclusion in this directory is not an endorsement.